Skip to main content
. 2022 Feb 14;22:114. doi: 10.1186/s12888-022-03758-w

Fig. 2.

Fig. 2

Proportion of Patients With CSWG During Treatment With Oral SGAs of Moderate to High Weight Gain Risk. BD-I, bipolar I disorder; CSWG, clinically significant weight gain; SGA, second-generation antipsychotic; SZ, schizophrenia; Tx, treatment